3. U.S. Patent Application Serial Number: (t0 be assigned)
Filed: October 13, 2009
Title: "Use of a Novel Alpha-7 nACHr Antagonist to Suppress Pathogenic Signal
Transduction in Cancer and AIDS”
Inventors: Drs. Peter A. Crooks, Linda P. Dwoskin, Zhenfa Zhang, and
Guangrong Zheng (Pharrnaceutical Sciences) and Roger L. Papke, Gretchen
Lopez Hernandez and Jeffrey Thinschmidt (outside inventors).
Technical Description: This invention provides a method for the use of select
quaternary ammonium antagonists to alpha-7 nAChR for the treatment of cancer
and HIV and AIDS.
Su1nmary: Several ofthe deadly symptoms of lung cancer and AIDs are thought
to be mediated [or aggravated] by the stimulation neuronal nicotinic acetylcholine
receptors [nACHr]. The inventors have proposed a method of treating some
symptoms of lung cancer and AIDS by blocking the activity of nACHr with
quaternary ammonium antagonists.
4. U.S. Patent Application Serial Number: (to be assigned)
Filed: October 29, 2009
Title: "Methods and Compositions for Treating Tumors and Metastases through
the Modulation of Latexin”
Inventors: Drs. Gary Van Zant and Ying Liang (Internal Medicine/ Hematology)
Teclmical Description: This invention relates to methods for treating cancers
and metastatic disease by modulating latexin expression and/or latexin activity.
Su1nmary: Cancer remains the second leading cause of death worldwide, despite
prolonged and concentrated efforts to develop cures. The inventors have
discovered that tumor growth in animals can be inhibited by increasing the
activity of latexin, an enzyme already present in animals. The inventors propose
that cancer can be treated in humans by increasing the activity of latexin in
humans.
5. U.S. Patent Application Serial Number: (to be assigned)
Filed: November 4, 2009
Title: "Intranasal Benzodiazepine Compositions”
Inventor: Dr. Daniel Werrneling (Pharrnacy Practice and Science)
Teclmical Description: This invention relates to benzodiazepine compositions
forrnulated to be delivered intranasally.
Su1nmary: Benzodiazepines are drugs that been used to treat a wide variety of
clinical conditions, including anxiety, convulsions, and spasticity. Successful
treatment of these conditions requires a strict adherence to the prescribed schedule
of administration. However, many benzodiazepines are administered
intravenously, which is painful and known to be associated with a higher level of
treatment avoidance by patients. The inventor has devised formulations of
benzodiazepine compositions that can be administered intranasally, a mode which
is associated with a higher rate of patient compliance with prescribed schedules.